X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs STERLING BIOTECH - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE STERLING BIOTECH CADILA HEALTHCARE/
STERLING BIOTECH
 
P/E (TTM) x 17.6 -0.4 - View Chart
P/BV x 4.2 0.0 25,945.7% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 CADILA HEALTHCARE   STERLING BIOTECH
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
STERLING BIOTECH
Dec-13
CADILA HEALTHCARE/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs55811 5,314.3%   
Low Rs3623 10,632.4%   
Sales per share (Unadj.) Rs116.326.8 433.8%  
Earnings per share (Unadj.) Rs17.9-15.0 -119.5%  
Cash flow per share (Unadj.) Rs23.1-5.5 -423.4%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.454.9 155.6%  
Shares outstanding (eoy) m1,023.74267.87 382.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.00.3 1,524.9%   
Avg P/E ratio x25.7-0.5 -5,537.4%  
P/CF ratio (eoy) x19.9-1.3 -1,562.3%  
Price / Book Value ratio x5.40.1 4,250.3%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6641,862 25,281.5%   
No. of employees `00011.81.4 872.9%   
Total wages/salary Rs m18,545547 3,391.6%   
Avg. sales/employee Rs Th10,072.75,303.3 189.9%   
Avg. wages/employee Rs Th1,569.1403.8 388.5%   
Avg. net profit/employee Rs Th1,547.7-2,959.0 -52.3%   
INCOME DATA
Net Sales Rs m119,0497,181 1,657.9%  
Other income Rs m1,13243 2,657.3%   
Total revenues Rs m120,1817,223 1,663.8%   
Gross profit Rs m28,475947 3,007.2%  
Depreciation Rs m5,3882,543 211.9%   
Interest Rs m9114,377 20.8%   
Profit before tax Rs m23,308-5,931 -393.0%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644-1,924 -293.3%   
Profit after tax Rs m18,292-4,007 -456.6%  
Gross profit margin %23.913.2 181.4%  
Effective tax rate %24.232.4 74.6%   
Net profit margin %15.4-55.8 -27.5%  
BALANCE SHEET DATA
Current assets Rs m82,00514,335 572.1%   
Current liabilities Rs m60,72049,809 121.9%   
Net working cap to sales %17.9-494.0 -3.6%  
Current ratio x1.40.3 469.3%  
Inventory Days Days73403 18.1%  
Debtors Days Days98171 57.6%  
Net fixed assets Rs m83,70355,432 151.0%   
Share capital Rs m1,024268 382.2%   
"Free" reserves Rs m86,42113,935 620.2%   
Net worth Rs m87,44514,701 594.8%   
Long term debt Rs m25,5519,478 269.6%   
Total assets Rs m180,65373,988 244.2%  
Interest coverage x26.6-0.4 -7,489.6%   
Debt to equity ratio x0.30.6 45.3%  
Sales to assets ratio x0.70.1 679.0%   
Return on assets %10.60.5 2,122.2%  
Return on equity %20.9-27.3 -76.8%  
Return on capital %22.0-6.4 -342.2%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m42,6831,860 2,295.0%   
Fx outflow Rs m11,24225 45,166.7%   
Net fx Rs m31,4411,835 1,713.5%   
CASH FLOW
From Operations Rs m9,1931,719 534.9%  
From Investments Rs m-9,737-3,148 309.3%  
From Financial Activity Rs m5151,426 36.1%  
Net Cashflow Rs m-29-3 852.9%  

Share Holding

Indian Promoters % 74.8 33.9 220.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.0 -  
FIIs % 5.9 9.9 59.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 11.0 39.3 28.0%  
Shareholders   44,069 21,482 205.1%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

DR. LAL PATHLABS LTD Surges by 7%; BSE HEALTHCARE Index Up 1.6% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

DR. LAL PATHLABS LTD share price has surged by 7% and its current market price is Rs 1,040. The BSE HEALTHCARE is up by 1.6%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 7.4%) and CADILA HEALTHCARE (up 5.4%). The top losers are THYROCARE TECHNOLOGIES and SANOFI INDIA (down 0.2%).

CADILA HEALTHCARE Surges by 5%; BSE HEALTHCARE Index Up 1.4% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

CADILA HEALTHCARE share price has surged by 5% and its current market price is Rs 358. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index is CADILA HEALTHCARE (up 5.2%). The top losers are THYROCARE TECHNOLOGIES and PFIZER .

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 17, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS